Dianthus Therapeutics, Inc. /DE/ (DNTH) Net Income (Loss) Attributable to Parent USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2024.
  • Dianthus Therapeutics, Inc. /DE/ Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$13.7 M, a 93.9% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$50.2 M, a 63.6% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Income (Loss) Attributable to Parent for 2023 was -$43.6 M, a 53% decline from 2022.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Income (Loss) Attributable to Parent for 2022 was -$28.5 M, a 117% decline from 2021.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Income (Loss) Attributable to Parent for 2021 was -$13.1 M, a 82.5% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$50.2 M -$13.7 M -$6.66 M -93.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$43.6 M -$10.6 M -$447 K -4.42% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$43.1 M -$14.8 M -$6.98 M -89.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$36.1 M -$11.1 M -$5.45 M -95.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-09
Q1 2023 -$30.7 M -$7.09 M -$2.21 M -45.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$28.5 M -$10.1 M -$48.9 M -126% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $20.4 M -$7.78 M +$9.64 M +55.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $10.7 M -$5.7 M +$11.2 M +66.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$501 K -$4.88 M +$12.6 M +72.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$13.1 M $38.7 M +$56.9 M Oct 1, 2021 Dec 31, 2021 8-K 2023-12-21
Q3 2021 -$70 M -$17.4 M +$251 K +1.42% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$70.3 M -$16.9 M +$2.15 M +11.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$72.4 M -$17.5 M +$2.52 M +12.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$74.9 M -$18.2 M +$5.07 M +21.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 -$80 M -$17.7 M +$3.31 M +15.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$83.3 M -$19.1 M -$1.37 M -7.74% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$81.9 M -$20 M -$5.18 M -34.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$76.8 M -$23.2 M -$6.56 M -39.3% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-03
Q3 2019 -$70.2 M -$21 M -$4.98 M -31.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$65.2 M -$17.7 M -$4.05 M -29.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$61.2 M -$14.8 M -$3.67 M -32.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$57.5 M -$16.7 M -$8.64 M -108% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 -$48.9 M -$16 M -$9.1 M -132% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-03
Q2 2018 -$39.8 M -$13.7 M +$2.07 M +13.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-03
Q1 2018 -$41.8 M -$11.2 M -$6.35 M -132% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-03
Q4 2017 -$35.5 M -$8.04 M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-19
Q3 2017 -$6.91 M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-19
Q2 2017 -$15.7 M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-19
Q1 2017 -$4.81 M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.